FRANKFURT, Jan 22 (Reuters) – The Bayer (BAYGn.DE) investor Union Funding criticized Bayer's chair for an absence of engagement, akin to exploring a spin-off of the corporate's shopper well being division, in line with an interview in WirtschaftsWoche.
Bayer is going through calls for from activist investor Bluebell Capital Companions to interrupt up, with a sale of the corporate's shopper well being unit and, at a later stage, for a separation of Bayer's prescription drugs and agriculture companies.
Bayer Chair Norbert Winkeljohann “does search dialogue with traders, however he ought to have initiated extra,” Markus Manns, portfolio supervisor at Union Funding, advised WirtschaftsWoche.
“It might undoubtedly have been a matter for the supervisory board to assist provoke a spin-off of Client Well being,” Manns added. He famous that chairs at opponents are far more engaged in creating worth for shareholders.
Winkeljohann didn't instantly reply to a request for remark.
A spokesperson for Bayer declined to touch upon Union Funding's place. “However usually talking we're all the time open to a constructive dialogue with our stakeholders,” the spokesperson mentioned.
Reporting by Tom Sims
Modifying by Tomasz Janowski
: .
